Table 1 Demographic characteristics of patients for HSDS analysis^a

Age at GH start, years

n = 71

n = 58

n = 129

 Mean (SD)

4.98 (4.73)

3.74 (4.18)

4.42 (4.51)

 Median (range)

3.06 (0.15–17.56)

1.80 (0.39–15.81)

2.15 (0.15–17.56)

Female, %

59%

40%

50%

Baseline BA/CA ratio^b

n = 15

1.04 (0.17)

n = 13

0.79 (0.31)

n = 28

0.92 (0.27)

Final BA/CA ratio^b

n = 32

1.04 (0.18)

n = 27

0.88 (0.17)

n = 59

0.97 (0.19)

GH baseline dose, mg/kg/d

n = 71

0.03 (0.01)

n = 58

0.03 (0.01)

n = 129

0.03 (0.01)

GH final dose, mg/kg/d^b

n = 61

0.03 (0.01)

n = 55

0.03 (0.01)

n = 116

0.03 (0.01)

IGF-1 SDS^b

n = 31

−0.58 (1.79)

n = 34

− 0.84 (1.72)

n = 65

− 0.71 (1.75)

Baseline height, cm

n = 71

95.00 (33.47)

n = 58

88.75 (27.61)

n = 129

92.19 (31.01)

Baseline weight, kg

n = 71

24.65 (24.22)

n = 58

17.47 (18.56)

n = 129

21.42 (22.07)

Last recorded height, cm

n = 71

124.2 (31.14)

n = 58

122.1 (27.65)

n = 129

123.2 (29.52)

Mid-parental target height, cm^b

n = 60

164.1 (25.33)

n = 38

174.5 (8.37)

n = 98

168.1 (21.04)

Baseline HSDS

n = 71

−1.17 (1.40)

n = 58

−1.94 (1.52)

n = 129

− 1.52 (1.50)

Final HSDS

n = 71

−0.28 (1.27)

n = 58

− 0.72 (1.11)

n = 129

− 0.48 (1.22)

Years of follow-up

n = 71

n = 58

n = 129

 Mean (SD)

2.39 (1.33)

2.59 (1.29)

2.48 (1.31)

 Median (range)

2.57 (0.06, 3.93)

3.10 (0.16, 3.98)

2.63 (0.06, 3.98)